ROBERT GERTGE: Open Payments
NPI 1356402374 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$798 in 36 payments from 22 companies in 2025. Trend: 2023 $806 · 2024 $911 · 2025 $798
Food & beverage: $713Education: $85
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| Astellas Pharma US Inc | 1 | $85 |
| Amgen Inc. | 3 | $69 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 3 | $31 |
| Lundbeck LLC | 1 | $30 |
| Organon LLC | 2 | $28 |
| Neuronetics, Inc. | 1 | $28 |
Products named: CAPLYTA, VRAYLAR, EVENITY, REXULTI, INGREZZA, VOQUEZNA, NEXPLANON, NEUROSTAR TMS THERAPY SYSTEM.
Industry payments across UT — which companies pay providers there.
